Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $181,125.78 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 1,551 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.78, for a total value of $181,125.78. Following the completion of the sale, the insider now owns 19,544 shares in the company, valued at approximately $2,282,348.32. The trade was a 7.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Julie Cooke also recently made the following trade(s):

• On Monday, February 10th, Julie Cooke sold 700 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $118.28, for a total value of $82,796.00.
• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $115.02 on Friday. The stock has a 50-day moving average of $137.83 and a two-hundred day moving average of $130.54. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The stock has a market cap of $11.65 billion, a PE ratio of 34.96 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. As a group, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 6.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of NBIX. Dodge & Cox raised its stake in shares of Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after purchasing an additional 1,728,605 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Neurocrine Biosciences in the fourth quarter worth about $115,193,000. Wellington Management Group LLP raised its stake in shares of Neurocrine Biosciences by 102.9% in the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after purchasing an additional 739,199 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company’s stock worth $100,705,000 after purchasing an additional 711,970 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares during the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. UBS Group increased their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Bank of America dropped their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Wedbush dropped their price target on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research report on Friday, February 7th. Finally, Royal Bank of Canada dropped their price target on Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating on the stock in a research report on Friday, February 7th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $166.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.